Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...

At least one of these had to include Avastin (bevacizumab). ELAHERE demonstrated an ORR by investigator of 31.7%, including five complete responses (CRs) The median DOR by investigator was 6.9 months.